Fixed-dose combination therapy: Panacea or poison?

Intensive Care Medicine

Volumn 24, Issue 4, 1998, Pages 283-285

  Rao, R B ^a   Goldfrank, L R ^a  

^a NEW YORK CITY POISON CONTROL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; HYDROCHLOROTHIAZIDE;

DRUG COMBINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EDITORIAL; HUMAN; HYPERKALEMIA; ORAL DRUG ADMINISTRATION;

EID: 0031924507     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340050569     Document Type: Editorial

References (19)

1. 1. Physician’s Desk Reference Fifty-first Edition (1997) Medical Economics. Montvale, New Jersey
2. 2. M Epstein G Bakris 1996 Newer approaches to antihypertensive therapy — Use of fixed-dose combination therapy Arch Intern Med 156 1969 1978 8823150 10.1001/archinte.156.17.1969 1:CAS:528:DyaK28XmsFSrsrk%3D Epstein M, Bakris G (1996) Newer approaches to antihypertensive therapy — Use of fixed-dose combination therapy. Arch Intern Med 156:1969–1978
3. 3. M Epstein 1996 The benefits of ACE inhibitors and calcium antagonists on slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy Ren Fail 18 813 832 8948517 10.3109/08860229609047709 1:CAS:528:DyaK2sXivFyiuw%3D%3D Epstein M (1996) The benefits of ACE inhibitors and calcium antagonists on slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy. Ren Fail 18: 813–832
4. 4. DA Sica 1994 Fixed-dose combination antihypertensive drugs — Do they have a role in rational therapy? Drugs 48 16 24 7525192 10.2165/00003495-199448010-00003 1:STN:280:ByqD2cvpsF0%3D Sica DA (1994) Fixed-dose combination antihypertensive drugs — Do they have a role in rational therapy? Drugs 48:16–24
5. 5. J Menard M Bellet 1993 Calcium antagonists-ACE inhibitors combination therapy: objective and methodology of clinical development J Cardiovasc Pharmacol 21 S49 S54 7692151 10.1097/00005344-199302000-00009 Menard J, Bellet M (1993) Calcium antagonists-ACE inhibitors combination therapy: objective and methodology of clinical development. J Cardiovasc Pharmacol 21: S49-S54
6. 6. GL Bakris B Williams 1995 Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens 13 S95 S101 10.1097/00004872-199508001-00016 1:CAS:528:DyaK2MXoslSmsb4%3D Bakris GL, Williams B (1995) Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens 13: S95-S101
7. 7. K Ratheiser J Dusleag K Seitl G Titscher W Klein 1992 A “lipo-protective” effect of a fixed combination of Captopril and hydrochlorothiazide in antihypertensive therapy Clin Cardiol 15 647 654 1395199 10.1002/clc.4960150906 1:STN:280:ByyD3cbit10%3D Ratheiser K, Dusleag J, Seitl K, Titscher G, Klein W (1992) A “lipo-protective” effect of a fixed combination of Captopril and hydrochlorothiazide in antihypertensive therapy. Clin Cardiol 15:647–654
8. 8. SA Eisen DK Miller RS Woodward E Spitznagel TR Pryzbeck 1990 The effect of prescribed daily dose frequency on patient medication compliance Arch Intern Med 150 1881 1884 2102668 10.1001/archinte.150.9.1881 1:STN:280:By%2BA28rls1A%3D Eisen SA, Miller DK, Woodward RS, Spitznagel E, Pryzbeck TR (1990) The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150:1881–1884
9. 9. CT Dollery 1977 Pharmacological basis for combination therapy of hypertension Ann Rev Pharmacol Toxicol 17 311 323 10.1146/annurev.pa.17.040177.001523 1:CAS:528:DyaE2sXks1ahs7s%3D Dollery CT (1977) Pharmacological basis for combination therapy of hypertension. Ann Rev Pharmacol Toxicol 17:311–323
10. 10. ME Davidof FE Becker J Hollifield 1987 Serum magnesium and potassium levels in hypertensive patients after a therapeutic switch from hydrochlorothiazide plus a potassium supplement to Maxzide Am J Med 82 Suppl 3 A 48 51 10.1016/0002-9343(87)90132-X Davidof ME, Becker FE, Hollifield J (1987) Serum magnesium and potassium levels in hypertensive patients after a therapeutic switch from hydrochlorothiazide plus a potassium supplement to Maxzide. Am J Med 82 (Suppl 3 A): 48–51
11. 11. AJ Bayer R Farag S Browne MSJ Pathy 1986 Plasma electrolytes in elderly patients taking fixed combination diuretics Postgrad Med J 62 159 162 3714599 10.1136/pgmj.62.725.159 1:STN:280:DyaL283jt12rtw%3D%3D Bayer AJ, Farag R, Browne S, Pathy MSJ (1986) Plasma electrolytes in elderly patients taking fixed combination diuretics. Postgrad Med J 62:159–162
12. 12. R Krakauer M Lauritzen 1978 Diuretic therapy and hypokalemia in geriatric outpatients Dan Med Bull 25 126 129 648201 1:STN:280:CSeC28fis1Q%3D Krakauer R, Lauritzen M (1978) Diuretic therapy and hypokalemia in geriatric outpatients. Dan Med Bull 25:126–129
13. 13. L Jaffey A Martin 1981 Malignant hyperkalemia after amiloride/hydrochlorothiazide treatment (Letter) Lancet 1 1272 1272 6112601 10.1016/S0140-6736(81)92450-8 1:STN:280:Bi6C1MnksVY%3D Jaffey L, Martin A (1981) Malignant hyperkalemia after amiloride/hydrochlorothiazide treatment. (Letter) Lancet 1:1272
14. 14. TF Chiu MJ Bullard JC Chen SJ Liaw CJ Ng 1997 Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy Ann Emerg Med 30 612 615 9360571 10.1016/S0196-0644(97)70078-7 1:STN:280:DyaK1c%2FisFShsQ%3D%3D Chiu TF, Bullard MJ, Chen JC, Liaw SJ, Ng CJ (1997) Rapid life-threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann Emerg Med 30: 612–615
15. 15. L Andren L Weiner A Svensson L Hansson 1983 Enalapril with either a ‘very low’ or ‘low’ dose of hydrochlorothiazide is equally effective in essential hypertension. A double blind trial in 100 hypertensive patients J Hypertension 1 384 386 Andren L, Weiner L, Svensson A, Hansson L (1983b) Enalapril with either a ‘very low’ or ‘low’ dose of hydrochlorothiazide is equally effective in essential hypertension. A double blind trial in 100 hypertensive patients. J Hypertension 1: 384–386
16. 16. J Avorn M Chen R Hartley 1982 Scientific versus commercial sources of influence on prescribing behavior of physicians Am J Med 73 4 9 7091173 10.1016/0002-9343(82)90911-1 1:STN:280:DyaL383islOhsA%3D%3D Avorn J, Chen M, Hartley R (1982) Scientific versus commercial sources of influence on prescribing behavior of physicians. Am J Med 73: 4–9
17. 17. AS Nies SP Spielberg 1996 Principles of therapeutics JG Hardman LE Limbird PB Molinoff RW Ruddon AG Gilman The Pharmacologic Basis of Therapeutics 9th edn McGraw-Hill New York 53 53 Nies AS, Spielberg SP (1996) Principles of therapeutics. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds) The Pharmacologic Basis of Therapeutics. 9th edn. McGraw-Hill, New York, p 53
18. 18. JK Aronson 1994 What’s in a brand name? BMJ 308 1140 1141 8173456 1:STN:280:ByuB38jmsl0%3D Aronson JK (1994) What’s in a brand name? BMJ 308:1140–1141
19. 19. MG Myers 1990 New drugs for hypertension: Should data precede conclusions? Can Med Assoc J 143 265 267 1:STN:280:DyaK3czksFemtw%3D%3D Myers MG (1990) New drugs for hypertension: Should data precede conclusions? Can Med Assoc J 143: 265–267